Injections Marketing Portfolios 
The Dermatology Digest
DECEMBER 18, 2024
Food and Drug Administration (FDA) has approved STEQEYMA (ustekinumab-stba), a biosimilar to STELARA (ustekinumab), for subcutaneous injection or intravenous infusion in adult and pediatric patients with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn’s disease and ulcerative colitis. immunology market.”
The Dermatology Digest
MAY 5, 2025
FDA has approved Teva Pharmaceuticals and Alvotechs Selarsdi injection, a biosimilar to Stelara ((ustekinumab), as an interchangeable treatment for inflammatory conditions. ” Interchangeability of SELARSDI with Stelara will further enable increased access for U.S. With two important biosimilars on the U.S. in May 2024.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AAAMS
APRIL 18, 2024
Introduction to Injectable Training Courses Injectable training courses are your fastest ticket from being a beginner to a pro in the cosmetic industry. The journey starts with understanding what injectables are – substances like Botox and fillers that enhance facial features and diminish and promote a youthful appearance.
The Dermatology Digest
SEPTEMBER 9, 2024
It incorporates Polyglutamic Acid (PGA), a peptide known for its hydrating properties The non-injectable Elastiderm Advanced Filler Concentrate is formulated with Acetyl Hexapeptide-1, to smooth wrinkles and add volume.
The Dermatology Digest
APRIL 1, 2024
“There remains a significant need for new, innovative treatment for vitiligo and other immune-mediated dermatologic conditions, and we look forward to working together with the CMS team to bringing these products to market in China.” The transaction is effective immediately upon the execution of the Collaboration and License Agreement.
AAAMS
FEBRUARY 22, 2023
You’ll Enter a Hot Market The global market for medical aesthetics is booming. Driven by pandemic-related trends that have normalized virtual work environments, market analysts are documenting record-breaking demand for aesthetic procedures. The market forecast for medical aesthetics has a projected 2027 value of $23.4
The Dermatology Digest
OCTOBER 1, 2024
Food and Drug Administration (FDA) are aligned on the regulatory pathway for ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX (onabotulinumtoxinA) as the reference product. market for all of BOTOX’s currently approved and future therapeutic indications under a single approval.”
Expert insights. Personalized for you.
69 
Let's personalize your content